Small Molecule vs Cell Therapy Clinical Trial Supply Chains

An introduction into the specific demands of the cell therapy supply chains in contrast to the more traditional small molecule supply pharmaceutical supply chain models.

This paper covers the start and end points of the processes, manufacturing and scheduling challenges and variability in the processes.

Understanding how these processes differ is critical for pharmaceutical developers who want to maximise efficiency when moving into the cell and gene therapy space.